Meeting
2022 ASCO Annual Meeting
Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).
Authors
Lawrence Chang
Gilead Sciences, Inc., Foster City, CA
Lawrence Chang , Peter S. Hall , Luciana Preger , Nikoleta Sjekloca , Estevan Bergamaco , Anne Broe , Plamena Petrova , Paul Berg , Adam Reich , Neha Pawar , Mahdi Gharaibeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1075)
DOI
10.1200/JCO.2022.40.16_suppl.1075
Abstract #
1075
Poster Bd #
453
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2021 ASCO Annual Meeting
Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
First Author: Joyce O'Shaughnessy
Poster
2021 ASCO Annual Meeting
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
First Author: Lisa A. Carey
Poster
2021 ASCO Annual Meeting
Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.
First Author: Majd Issa